Announced Date: 2023-11-20 (November 20, 2023)
Asset Name: HSK31858
Licensor: Haisco Pharmaceutical Group (China) and
Licensee (Buyer): Chiesi Farmaceutici S.p.A（Italy）
.
Asset Modality: Small Molecule, Oral
Asset Target: DPP1 (dipeptidyl peptidase 1 inhibitor)
Potential Indication: respiratory diseases
Current Stage: Phase II, in China
.
Scope of Authority:
Haisco has granted Chiesi an exclusive license to develop, manufacture, and commercialise outside greater China (including Hong Kong SAR, Macau SAR and Taiwan District) HSK31858.
.
Payment Detail:
Upfront payment of $13 million;
Milestone payments up to $462 million;
Total up to $475 million.
Additional royalties based on net sales in the licensed territories.
.
Link:
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis
